Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
The Expert Council has developed an algorithm for the diagnosis, treatment, and follow-up of patients with diabetes mellitus complicated by diabetic polyneuropathy (DPN), intended for use in both outpatient and inpatient settings. Particular emphasis is placed on the importance of early detection of DPN and interdisciplinary collaboration among specialists. The proposed algorithm includes recommendations for screening, clinical and instrumental diagnostics, risk stratification, and therapy selection based on the neuropathy phenotype, as well as the staged application of pathogenetic and symptomatic treatments, criteria for evaluating effectiveness, and indications for therapy continuation or adjustment. Experts highlighted the pathogenetic rationale for prescribing agents with neuroprotective and co-analgesic effects, including ipidacrine, which has proven efficacy and a legal basis for use in DPN. The algorithm promotes the standardization of care and can be integrated into the clinical practice of primary care physicians, endocrinologists, and neurologists.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.17116/jnevro2025125081102 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Plasma glucose and HbA1c discrepancy may indicate hemoglobinopathy: a case series.
Curr Med Res Opin
September 2025
Department of Internal Medicine, Taksim Training and Research Hospital, Istanbul, Turkey.
Introduction: Diabetes Mellitus is a chronic disease characterised by elevated plasma glucose (PG) levels. HbA1c has been widely utilized for diabetes diagnosis. However, certain conditions restrict its use.
View Article and Find Full Text PDFElectrochemical Sensors for Rapid Cardiovascular Disease Diagnostics.
ACS Sens
September 2025
METU MEMS Center, Ankara 06530, Türkiye.
Cardiovascular diseases (CVDs) remain a leading cause of death, particularly in developing countries, where their incidence continues to rise. Traditional CVD diagnostic methods are often time-consuming and inconvenient, necessitating more efficient alternatives. Rapid and accurate measurement of cardiac biomarkers released into body fluids is critical for early detection, timely intervention, and improved patient outcomes.
View Article and Find Full Text PDFConcomitant Comedications and Survival With First-Line Pembrolizumab in Advanced Non-Small-Cell Lung Cancer.
JAMA Netw Open
September 2025
Oncostat U1018, Institut National de la Santé et de la Recherche Médicale (INSERM), Ligue Contre le Cancer, Paris-Saclay University, Villejuif, France.
Importance: Antibiotics, steroids, and proton pump inhibitors (PPIs) are suspected to decrease the efficacy of immunotherapy.
Objective: To explore the association of comedications with overall survival (OS) in patients with advanced non-small-cell lung cancer (NSCLC).
Design, Setting, And Participants: This nationwide retrospective cohort study used target trial emulations of patients newly diagnosed with NSCLC from January 2015 to December 2022, identified from the French national health care database.
Critical Care Physicians' Perspectives on Nudging in Communication.
JAMA Netw Open
September 2025
Harvard Medical School, Boston, Massachusetts.
Importance: Research in behavioral economics has demonstrated that people have irrational biases, which make them susceptible to decisional shortcuts, or heuristics. The extent to which physicians consciously might use nudges to exploit these heuristics and thereby influence their patients' decision-making is unclear. In addition, ethical questions about the conscious use of nudges in medicine persist, yet little is known about how physicians experience and perceive their use.
View Article and Find Full Text PDFPolyomavirus Antibodies for Merkel Cell Carcinoma Recurrence Detection.
JAMA Dermatol
September 2025
Department of Dermatology, University of Washington, Seattle.
Importance: Merkel cell carcinoma (MCC) is typically caused by the Merkel cell polyomavirus (MCPyV) and recurs in 40% of patients. Half of patients with MCC produce antibodies to MCPyV oncoproteins, the titers of which rise with disease recurrence and fall after successful treatment.
Objective: To assess the utility of MCPyV oncoprotein antibodies for early detection of first recurrence of MCC in a real-world clinical setting.